Quest Diagnostics
819 hedge funds and large institutions have $14B invested in Quest Diagnostics in 2023 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 257 increasing their positions, 316 reducing their positions, and 83 closing their positions.
290% more call options, than puts
Call options by funds: $96.5M | Put options by funds: $24.7M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.87% less ownership
Funds ownership: 89.8% → 88.92% (-0.87%)
1% less capital invested
Capital invested by funds: $14.2B → $14B (-$169M)
2% less funds holding
Funds holding: 834 → 819 (-15)
16% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 83
19% less repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 316
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$190M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$93.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$73M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$60.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$50.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$82.3M |
| 2 |
Amundi
Paris,
France
|
-$77.7M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$46.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$45.6M |
| 5 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
-$38.2M |
DGX Hedge Fund Activity: Q2 2023 in Review
819 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2023, worth a combined $14B — down 1.2% from $14.2B a quarter earlier.
Sellers outnumbered buyers: 83 funds closed out of DGX and 70 opened new positions — a net loss of 13 holders — while 316 trimmed existing stakes and 257 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $190M. The largest seller was Pacer Advisors, cutting an estimated $82.3M.
- 819 institutional investors held Quest Diagnostics (DGX) as of Q2 2023, down from 834 in Q1 2023.
- Funds reported $14B of Quest Diagnostics stock for Q2 2023, down 1.2% quarter-over-quarter.
- 70 funds opened new Quest Diagnostics positions in Q2 2023 and 83 closed out, a net change of -13 holders.
- The largest Quest Diagnostics buyer in Q2 2023 was T. Rowe Price Associates, an estimated $190M added.
- The largest Quest Diagnostics seller in Q2 2023 was Pacer Advisors, an estimated $82.3M sold.
Based on aggregated 13F filings for Q2 2023.